Banner: investors

News Releases

PURE Bioscience Announces Co-Marketing and Supply Agreement with Roka Bioscience, Inc.

July 10, 2017

SAN DIEGO, CA (July 10, 2017) – PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced that it has entered into a two-year nonexclusive supply agreement with Roka Bioscience, Inc. (NASDAQ: ROKA) for Roka to market PURE’s line of antimicrobial disinfecting and sanitizing products and processing aids to the food industry. Roka is a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens.

With this Agreement PURE Bioscience expands Roka Bioscience’s reach into the operational environments of food production with environmental and surface disinfectants and processing interventions for pathogen control, complementing their Atlas foodborne pathogen testing portfolio.  

Hank R. Lambert, CEO of PURE said, “We are very excited to partner with Roka in offering advanced science in both pathogen detection and elimination to the food industry. Our proven silver dihydrogen citrate based antimicrobial solutions have been adopted by Chipotle, Taylor Farms, Subway® and numerous other food companies for effective pathogen reduction. Partnering with Roka will enable us to extend our solutions to their broad customer portfolio.”

Mary Duseau, CEO of Roka Bioscience stated, “Roka Bioscience continues to deliver technology forward solutions to the food industry. With the addition of the PURE Bioscience product line, Roka’s commitment to food safety now extends from the processing floor to the laboratory. We believe that this partnership and our solution approach offers the industry increased control and resolution in pathogen detection and prevention.”

About Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas® Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas® System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas® System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  For more information, visit

About PURE Bioscience, Inc. 

PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily in the food safety arena -- providing solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and it mitigates bacterial resistance. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at

Forward-looking Statements  

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company's current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing and to expand its use in OLR poultry processing; the Company’s ability to raise funds necessary to support its continued operations and the implementation of its business plan; competitive factors; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2016, its Form 10-Q for the first quarter ended October 31, 2016 and third quarter ended April 30, 2017. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.



Hank Lambert, CEO

Terri MacInnis, VP of IR

Tom Hemingway

PURE Bioscience, Inc.

Bibicoff + MacInnis, Inc.

Redwood Investment Group

619-596-8600 ext.103